Purpose: Nowadays, chromosomal regions containing genes associated with the risk of lung cancer are identified by a number of genome-wide association studies (GWASs). As part of the study, GWAS has identified the association of six chromosomal regions, 1q23, 4q22, 4q31, 5p15, 6p21, and 15q25, as being associated with lung cancer risk in the European population. We investigated the impact of genetic variants identified in GWASs for lung cancer susceptibility on the survival outcomes in patients with early stage non-small cell lung cancer (NSCLC). Materials and Methods: Three hundred and sixty-three patients with surgically resected NSCLC were enrolled. Eight single nucleotide polymorphisms (SNPs), rs2808630 on 1q23, rs7671167 on 4q22, rs1489759 and rs2202507 on 4q31, rs2736100 and rs402710 on 5p15, rs1052486 on 6p21 and rs16969968 on 15q25, were genotyped using a polymerase chain reaction-restriction fragment length polymorphism assay. The associations between genotypes and overall survival (OS) and disease-free survival (DFS) were analyzed. Results: None of the eight SNPs were significantly associated with OS or DFS. In addition, when the patients were categorized according to age, gender, smoking status, tumor histology and pathologic stage, there were no significant associations between the eight SNPs and the survival outcomes. Conclusion: These results suggest that the genetic variants identified by GWASs for lung cancer susceptibility may not affect the prognosis of early stage NSCLC. (J Lung Cancer 2012;11(2):66 70)
INTRODUCTION
The tumor-node-metastais (TNM) staging system is the best index for determining the survival outcome after surgical resection of early-stage non-small cell lung cancer (NSCLC) (1) . However, patients with the same pathologic stage of the disease display marked variability in recurrence and survival, likely due to heterogeneity of gene/protein expression profiles (2) . A better understanding of the molecular pathways that influence the lung cancer phenotype may lead to the identification of patients at high risk of recurrence, and thus, interventions could be directed toward those who are most likely to benefit from them.
Recently, a number of genome-wide association studies (GWASs) have identified chromosomal regions containing genes associated with the risk of lung cancer. In addition, GWASs have aided our understanding of diverse molecular pathways underlying lung cancer by identifying a number of genes potentially involved in the pathogenesis of this disease (3) (4) (5) (6) (7) (8) . There is a growing realization that genetic polymorphisms influence not only the development of cancer, but also cancer progression and prognosis (9, 10) . Therefore, we have hypothesized that genetic variants associated with susceptibility to lung cancer in these GWASs may affect malignant phenotypes of lung cancer and thereby affect the prognosis of lung cancer patients. To test this hypothesis, we investigated the impact of genetic variants identified in GWASs for lung cancer susceptibility on the survival outcomes in patients with early stage NSCLC.
MATERIALS AND METHODS
This study included patients (n=363) with stage I, II, or IIIA 
RESULTS
Clinical and pathologic characteristics of the patients and their association with OS are shown in Table 1 
DISCUSSION AND CONCLUSION
Several studies have reported that certain functional SNPs can contribute to cancer susceptibility and survival (10-13).
Therefore, it was hypothesized that some of the genetic variants associated with lung cancer susceptibility in GWASs (3-8) can also affect the natural history of lung cancer, such as the stage or grade of disease, the rate of disease progression or the propensity for metastasis, thereby influencing the survival outcomes. In the present study, however, no significant associations were found between the eight genetic variants identified in the GWASs and the survival outcomes of patients with early Table 2 . In conclusion, the present study demonstrates that the genetic variants identified by GWASs for lung cancer susceptibility are not significantly associated with the prognosis of patients with early stage NSCLC. However, because this is the first study of genetic variants identified in GWASs in relation to the survival of lung cancer, additional studies with larger and more diverse study populations are required in order to confirm our findings.
